Clinical Trials Logo

Clinical Trial Summary

Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland. As humans grow older the levels of DHEA naturally decrease. Low levels of DHEA have been associated with a variety of harmful effects, including increased heart disease, decreased immune system function, decreased bone density (osteoporosis), high cholesterol, and increased fat to muscle ratio.

Blood levels of DHEA and its sulfate form, DHEA-S, begin dropping when humans are in their 20's. By the time humans are in their 40's and 50's, levels of DHEA and DHEA-S levels are at 50% of their peak. Previous studies have shown that levels of these hormones are associated with feelings of "well-being" and enjoyment of "leisure" activities.

In this study researchers are interested in the effects on mood and behavior of DHEA in men and women with mid-life related mood disorders. Specifically, researchers would like to find out if increasing levels of DHEA will lessen the symptoms associated with these disorders.


Clinical Trial Description

Dehydroepiandrosterone (DHEA) is a hormone produced by the adrenal gland in concentrations that decrease with age. In humans low DHEA levels have been associated with a variety of adverse biological consequences, including increased cardiovascular disease, decreased immune function, decreased bone density, negative lipid profile and an increased fat to muscle ratio.

In this study, we investigate the effects on mood and behavior of DHEA in men and women with midlife-related mood disorders in a double-blind, placebo-controlled, crossover trial. We specifically ask whether increasing DHEA levels will mitigate any or all of the neurasthenia-like symptoms characteristic of these disorders. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00001487
Study type Interventional
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase Phase 2
Start date June 1995
Completion date April 2004

See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A